Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY).

IL-33 inhibitor itepekimab for chronic obstructive pulmonary disease (COPD), and vaccines against acne, extra-intestinal pathogenic Escherichia coli (EPEC), and respiratory syncytial virus (RSV).

Meanwhile, the clinical trial programme for IL-33 inhibitor itepekimab is being expanded into CRSwNP, along with COPD and bronchiectasis. Phase 3 data is expected later this year for COPD ...

The table below is a review of notable updates that occurred in May 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage ...